David Trueman

507 total citations
48 papers, 366 citations indexed

About

David Trueman is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, David Trueman has authored 48 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Economics and Econometrics, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in David Trueman's work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Pharmaceutical Economics and Policy (11 papers) and Heart Failure Treatment and Management (5 papers). David Trueman is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (19 papers), Pharmaceutical Economics and Policy (11 papers) and Heart Failure Treatment and Management (5 papers). David Trueman collaborates with scholars based in United States, United Kingdom and Switzerland. David Trueman's co-authors include Elizabeth Hancock, C. Deschaseaux, Osman B. Kavcar, Chris D. Poole, Michael J. Lacey, Anthony Bentley, John J.V. McMurray, Joaquim Cristino, Matthew Taylor and Andrew Briggs and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

David Trueman

40 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Trueman United States 12 91 85 52 52 44 48 366
Philip L. Cyr United States 9 22 0.2× 61 0.7× 42 0.8× 43 0.8× 54 1.2× 37 361
Craig Robbins United States 10 92 1.0× 40 0.5× 33 0.6× 19 0.4× 18 0.4× 12 403
Élisabeth Martin United States 11 35 0.4× 65 0.8× 105 2.0× 17 0.3× 39 0.9× 35 376
S. Cure United Kingdom 16 60 0.7× 19 0.2× 57 1.1× 34 0.7× 33 0.8× 39 565
Miriam Hattle United Kingdom 7 36 0.4× 69 0.8× 45 0.9× 26 0.5× 20 0.5× 17 286
Matthew Sussman United States 9 31 0.3× 62 0.7× 46 0.9× 79 1.5× 23 0.5× 30 364
Laura Cohen United States 11 34 0.4× 165 1.9× 39 0.8× 27 0.5× 24 0.5× 33 448
John Akassi Ghana 12 24 0.3× 123 1.4× 14 0.3× 70 1.3× 34 0.8× 15 610
Elizabeth Dee United States 9 16 0.2× 68 0.8× 113 2.2× 38 0.7× 68 1.5× 25 344

Countries citing papers authored by David Trueman

Since Specialization
Citations

This map shows the geographic impact of David Trueman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Trueman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Trueman more than expected).

Fields of papers citing papers by David Trueman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Trueman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Trueman. The network helps show where David Trueman may publish in the future.

Co-authorship network of co-authors of David Trueman

This figure shows the co-authorship network connecting the top 25 collaborators of David Trueman. A scholar is included among the top collaborators of David Trueman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Trueman. David Trueman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Santos, Sandra, Tara M. Robinson, & David Trueman. (2025). Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data. Advances in Therapy. 42(11). 5781–5793.
3.
Hu, Xiao, Cheryl Abbas, Sue Richardson, et al.. (2023). Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy. European Journal of Cardiovascular Nursing. 22(Supplement_1). 2 indexed citations
4.
Desai, Nihar R., et al.. (2022). COST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS. Journal of the American College of Cardiology. 79(9). 1559–1559. 1 indexed citations
5.
Desai, Nihar R., et al.. (2022). Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. American Journal of Cardiovascular Drugs. 22(5). 545–556. 31 indexed citations
6.
7.
Hancock, Elizabeth, et al.. (2020). An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Advances in Therapy. 37(3). 1233–1247. 25 indexed citations
8.
Trueman, David, et al.. (2018). PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE. Value in Health. 21. S106–S106. 1 indexed citations
9.
Ademi, Zanfina, Elizabeth Hancock, David Trueman, et al.. (2016). Cost-Effectiveness of Sacubitril/Valsartan (Formerly LCZ696) in Chronic Heart Failure Patients with Reduced Ejection Fraction - An Analysis for Switzerland. Value in Health. 19(7). A655–A655. 1 indexed citations
10.
11.
12.
McMurray, John J.V., Martín Cowie, Andrew Briggs, et al.. (2015). A New Cost-Effectiveness Modelling Approach In Chronic Heart Failure With Reduced Ejection Fraction. Value in Health. 18(7). A394–A394. 2 indexed citations
13.
Schechter, Michael S., et al.. (2015). Inhaled Aztreonam Lysine versus Inhaled Tobramycin in Cystic Fibrosis. An Economic Evaluation. Annals of the American Thoracic Society. 12(7). 1030–1038. 6 indexed citations
14.
15.
Webb, Nicholas J.A., Martín Cowie, Andrew Briggs, et al.. (2015). The Cost-Effectiveness Of Treatment For Chronic Heart Failure: A Systematic Review. Value in Health. 18(7). A391–A391. 1 indexed citations
16.
17.
18.
19.
Trueman, David, et al.. (2013). Technical Errors in Cost-Effectiveness Models: Evidence from the Single Technology Appraisal Programme in England and Wales. Value in Health. 16(7). A592–A592. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip L. Cyr Breakdown of academic impact, for papers by Craig Robbins Breakdown of academic impact, for papers by Élisabeth Martin Breakdown of academic impact, for papers by S. Cure Breakdown of academic impact, for papers by Miriam Hattle Breakdown of academic impact, for papers by Matthew Sussman Breakdown of academic impact, for papers by Laura Cohen Breakdown of academic impact, for papers by John Akassi Breakdown of academic impact, for papers by Elizabeth Dee
Rankless by CCL
2026